Abstract
Finding a causal gene from case-control studies is a classic and fundamental problem in genomics. To date, we still ask which genes are differentially regulated by a disease with single-cell sequencing data, but in a cell-type-specific way. Here, we present a causal inference framework that effectively adjusts confounding effects, not requiring prior knowledge of control genes or cells. We demonstrate that our causal inference algorithm substantially improves statistical power in simulations and real-world data analysis of 70k brain cells, collected for dissecting Alzheimer’s disease (AD) mechanisms. We identified that 377 causal genes are differentially regulated by the disease in various brain cell types, including highly-relevant AD genes with a proper cell type annotation, such as DGKD in neurons, SNCA in microglia, PIAS in oligodendrocyte progenitor cells, and FGFR2 in astrocytes. Causal genes in different cell types also enrich distinctive pathways, highlighting multiple components of the disease progressions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH grants U01NS110453, U24-HG009446, and U01-RFA-HG009088 (MK). We also acknowledge generous supports from the BC Cancer Foundation, Project ID 1NSRG048 (YPP).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.synapse.org). Study data were provided by the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants RF1AG57473 (single nucleus RNAseq) and the Illinois Department of Public Health (ROSMAP). The Religious Orders Study and Rush Memory and Aging Project were approved by an IRB of Rush University Medical Center.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact: Yongjin Park: ypp{at}stat.ubc.ca, Manolis Kellis: manoli{at}mit.edu
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos